For full-year 2026, COLL expects net product revenues of $805M–$825M, vs estimate of 808.8M and adjusted EBITDA of $455M–$475M.
https://seekingalpha.com/news/4537755-collegium-pharmaceutical-issues-2026-revenue-guidance-in-line-with-estimates
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.